Gregory M. Sullivan M.D. is currently Chief
Medical Officer at Tonix Pharmaceuticals. He oversees the medical
aspects of the company's clinical research and development programs,
which are focused on common disorders of the central nervous system. Dr. Sullivan has over two decades of experience in the diagnosis,
treatment and neurobiology of anxiety and mood disorders. Formerly, Dr.
Sullivan served as Assistant Professor of Psychiatry in the Department
of Psychiatry at Columbia University Medical Center, as a Research
Scientist at the New York State Psychiatric Institute, and as a
practicing psychiatrist. He
has also served as a member of the Institutional Review Board of the New
York State Psychiatric Institute since 2009.
Dr. Sullivan's areas of
expertise include the diagnosis, treatment and neurobiology of anxiety
and mood disorders, including Post Traumatic Stress Disorder (PTSD). As Principal Investigator and
Co-Investigator on several human studies of PTSD, Dr. Sullivan was responsible for the recruitment, biological assessments, treatment, and
safety of participants with PTSD in clinical trials of the disorder. He received
grants from the National Institute of Mental Health, the Anxiety
Disorders Association of America, and the American Foundation for
Suicide Prevention. Additionally, Dr. Sullivan has published more than
50 articles and chapters on research topics ranging from stress and
anxiety disorders to abnormal serotonergic receptor expression in
bipolar depression, PTSD and panic disorder.
Dr. Sullivan received his
medical doctorate from the College of Physicians & Surgeons at
Columbia University and completed his residency training in psychiatry
at Columbia University Medical Center. He completed a two-year National
Institutes of Health-sponsored research fellowship in anxiety and
affective disorders before joining the faculty at Columbia.
